Form 4: Quest Diagnostics EVP Reports Routine Stock Transactions

Catherine T. Doherty, EVP of Regional Businesses at Quest Diagnostics, reported the acquisition of shares from a performance award, subsequent tax-related dispositions, and a sale under a 10b5-1 plan.

Summary

• Catherine T. Doherty, Executive Vice President of Regional Businesses at Quest Diagnostics Inc. (DGX), reported several transactions involving the company's common stock.
• On March 4, 2026, Ms. Doherty acquired 11,364 shares of common stock at a price of $204.86 per share, resulting from the settlement of a performance stock award.
• Also on March 4, 2026, 5,806 shares of common stock were disposed of at $204.86 per share to cover tax withholding obligations related to the performance stock award settlement.
• On March 5, 2026, Ms. Doherty sold 5,558 shares of common stock at $206.21 per share, executed pursuant to a Rule 10b5-1 sales plan.
• Following these transactions, Ms. Doherty directly beneficially owns 67,122 shares of common stock.
• Additionally, Ms. Doherty indirectly holds 4,502 shares through the Company's tax-qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a standard disclosure of executive compensation and pre-planned stock sales, which are generally neutral in sentiment as they do not indicate a change in company fundamentals or management's outlook.

Positives

• The reporting person acquired 11,364 shares of common stock as a settlement of a performance stock award, indicating achievement of performance metrics.

Negatives

• A total of 11,364 shares were disposed of through tax withholding and a pre-planned sale, reducing direct beneficial ownership.

Industry Context

StockSavvy.ai notes that these types of insider transactions, involving the settlement of performance-based equity awards and subsequent tax-related dispositions and pre-planned sales, are routine occurrences for executives in publicly traded companies across various industries. They reflect standard executive compensation practices and personal financial planning.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine executive compensation and pre-planned sales, not indicative of new strategic direction or financial performance.

Key Dates

Recommendation

The filing details routine insider transactions related to executive compensation, including the settlement of a performance award, tax-related dispositions, and a pre-planned sale. These transactions do not provide new fundamental information to warrant a change in investment recommendation for Quest Diagnostics Inc.

Keywords

Quest Diagnostics, DGX, Insider Trading, Form 4, Stock Transaction, Performance Award, 10b5-1 Plan, Executive Compensation